



28 16. Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity,  
29 University of Melbourne, Melbourne, VIC, Australia

30 17. Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane,  
31 Australia

32 18. ADVANCE-ID, Saw Swee School of Public Health, National University of Singapore, Singapore

33 19. Infection Management and Prevention Service, Queensland Children's Hospital, Brisbane, QLD, Australia  
34

35 **Keywords:** long-read whole genome sequencing, bloodstream infection, artificial  
36 intelligence, machine-learning, nanopore

37

### 38 **ABSTRACT**

39 **Background:** Direct metagenomic sequencing from positive blood culture (BC) broths, to  
40 identify bacteria and predict antimicrobial susceptibility, has been previously demonstrated  
41 using Illumina-based methods, but is relatively slow. We aimed to evaluate this approach  
42 using nanopore sequencing to provide more rapid results.

43 **Methods:** Patients with suspected sepsis in 4 intensive care units were prospectively enrolled.  
44 Human-depleted DNA was extracted from positive BC broths and sequenced using nanopore  
45 (MinION). Species abundance was estimated using Kraken2, and a cloud-based artificial  
46 intelligence (AI) system (AREScLOUD) provided *in silico* antimicrobial susceptibility testing  
47 (AST) from assembled contigs. These results were compared to conventional identification  
48 and phenotypic AST.

49 **Results:** Genus-level agreement between conventional methods and metagenomic whole  
50 genome sequencing (MG-WGS) was 96.2% (50/52), but increased to 100% in  
51 monomicrobial infections. In total, 262 high quality AREScLOUD AST predictions across 24  
52 samples were made, exhibiting categorical agreement (CA) of 89.3%, with major error (MA)  
53 and very major error (VME) rates of 10.5% and 12.1%, respectively. Over 90% CA was

54 achieved for some taxa (e.g. *Staphylococcus aureus*), but was suboptimal for *Pseudomonas*  
55 *aeruginosa* (CA 50%). In 470 AST predictions across 42 samples, with both high quality and  
56 exploratory-only predictions, overall CA, ME and VME rates were 87.7%, 8.3% and 28.4%.  
57 VME rates were inflated by false susceptibility calls in a small number of species / antibiotic  
58 combinations with few representative resistant isolates. Time to reporting from MG-WGS  
59 could be achieved within 8-16 hours from blood culture positivity.

60 **Conclusions:** Direct metagenomic sequencing from positive BC broths is feasible and can  
61 provide accurate predictive AST for some species and antibiotics, but is sub-optimal for a  
62 subset of common pathogens, with unacceptably high VME rates. Nanopore-based  
63 approaches may be faster but improvements in accuracy are required before it can be  
64 considered for clinical use. New developments in nanopore sequencing technology, and  
65 training of AI algorithms on larger and more diverse datasets may improve performance.

66 **Abstract word count:** 311

67 **INTRODUCTION**

68 Sepsis is a major cause of morbidity and mortality. Rapid pathogen identification and  
69 antimicrobial susceptibility phenotyping is critical to selection of appropriate treatment and  
70 ensuring optimal patient outcomes (1, 2). Current pathogen identification and culture-based  
71 antimicrobial susceptibility testing (AST) can take up to 3 days, or longer. Consequently,  
72 rapid molecular detection and gene profiling methodologies are needed (2-4), especially in an  
73 era of an increasing prevalence of antimicrobial resistance.

74

75 We have previously demonstrated the application of Illumina-based sequencing from positive  
76 blood culture broths (5). This approach showed reasonable performance in both species-level  
77 identification and predictive AST from metagenomic data, but there were few advantages  
78 over conventional methods in terms of turn-around times to clinical reporting. In this study,  
79 we aimed to evaluate the use of nanopore sequencing, using a similar approach and an  
80 established DNA extraction method, to determine whether reductions in turn-around times  
81 can be achieved without sacrificing diagnostic performance. We compared a machine-  
82 learning based whole genome sequencing predictive AST tool to conventional culture-based  
83 methods, in order to determine whether such methods could be applicable in a diagnostic  
84 laboratory and achieve acceptable performance characteristics.

85

86 **METHODS**

87 This was a sub-study of the DIRECT program: a prospective, observational multicentre study  
88 of children and adults presenting to the intensive care unit (ICU) with clinical features of  
89 sepsis (6). Patients were screened for enrolment in four ICUs (3 adult, 1 paediatric) in  
90 Brisbane, Australia (Royal Brisbane and Women's Hospital, The Prince Charles Hospital,

91 Princess Alexandra Hospital and Queensland Children’s Hospital). Patients who met  
92 inclusion criteria and none of the exclusion criteria were eligible for enrolment (Table 1).

93

#### 94 ***Ethics***

95 Ethics approval was granted by the Children’s Health Queensland Hospital and Health  
96 Service Human Research Ethics Committee (HREC) [HREC/19/QCHQ/55177], with  
97 governance approvals for all participating sites. Written informed consent was obtained from  
98 all participants (or their parent or legal guardian). Approval was granted by the Queensland  
99 Civil and Administrative Tribunal [CRL024-19] to include patients unable to consent for  
100 themselves under the Guardianship and Administration Act 2000.

101

#### 102 ***Sampling***

103 This study included patients with positive blood cultures and presence of bacteria confirmed  
104 by Gram stain and microscopy. Samples with non-bacterial species (e.g. *Candida*) were  
105 excluded from further analysis (as the analysis pipelines are optimised for prokaryotic  
106 organisms). Samples with likely contamination (e.g. mixed coagulase-staphylococci), which  
107 were not worked-up further by the clinical lab for identification or susceptibility testing, were  
108 also not analysed further. For some samples, susceptibility testing was not routinely  
109 performed on cultured isolates (e.g. anaerobes), hence predictive AST was not assessed.

110

111 Blood culture bottles (FA plus, FN plus and paediatric PF plus bottles; bioMérieux) were  
112 removed from BACT/Alert Virtuo System once flagged positive with microbial growth on  
113 Gram stain. A de-identified 10 mL aliquot of the positive blood culture broth was processed  
114 by a blinded researcher in a separate research lab (The University of Queensland, Centre for  
115 Clinical Research), located on the same campus, within 1.5 hours (Figure 1). An uninoculated

116 blood culture broth was also sampled to determine the extent of background DNA  
117 contamination. Methods for DNA extraction have been detailed previously (5). In brief, host  
118 genomic DNA (gDNA) was depleted using the MolYsis Complete and MolYsis Basic kits  
119 (Molzym, Germany) 0.2mL and 1mL protocols, respectively, according to manufacturer's  
120 instructions, (with minor modifications), then centrifuged at 10,000g for 30 seconds and the  
121 supernatant removed (5). The microbial pellet then underwent further gDNA extraction using  
122 UltraClean kits. Samples were extracted for genomic DNA upon receipt and the remaining  
123 sample frozen at -80°C, and if required, thawed to room temperature from frozen.

124

125 DNA quality and purity checks were undertaken using the QUBIT fluorometer (Life  
126 Technologies), NanoDrop 2000 Spectrophotometer (Thermo Scientific) and Agilent  
127 TapeStation 4150 using Genomic DNA ScreenTape and Reagents. For comparison, cultured  
128 isolates from the positive BC broths were also retrieved from the clinical laboratory for WGS  
129 (Figure 1).

130

### 131 ***Sequencing***

132 Libraries were prepared using the Rapid Barcoding Sequencing or Nanopore Genomic DNA  
133 Ligation kit with Native barcoding according to manufacturer's instructions (Oxford  
134 Nanopore Technologies). Libraries were loaded into the R9.4.1 flow cell and run on the  
135 MinION MK1B device. After flow cell quality checks, all sequencing utilised the flow cell  
136 priming kit (EXP-FLP002) and sequencing commenced at -180mV; voltage drift was  
137 accounted for where the flow cell went through a wash protocol. The sequencing runs were  
138 monitored with MinKNOW version 21.05.25 core 4.3.12. Fast basecalling model was  
139 applied with Bream version 6.2.6 and Guppy version 5.0.16 (version 3.2.9 used prior to  
140 February 2021). Libraries were run for 72 hours. Final run QC analysis was undertaken with

141 PycoQC prior to bioinformatic analysis. In addition, pure colonies of bacteria isolated from  
142 positive blood cultures were also sequenced, using DNA extracted by QIAGEN DNeasy  
143 Ultraclean Microbial Kit, with quantification by Life Technologies QUBIT fluorometer and  
144 library preparation with Illumina ILMN DNA LP tagmentation. Library size was determined  
145 by Agilent TapeStation 4150 using D1000 High Sensitivity kit. Sequencing was performed  
146 on the Illumina MiniSeq platform with the 300 cycle output reagent kit (Figure 1).

147

#### 148 *Metagenome assemblies, taxonomic profiling and WGS-AST using machine-learning*

149 Assembly and binning for WGS-AST from metagenomes was performed using a previously  
150 published workflow (7). Raw reads were trimmed and quality filtered using Nanofilt 2.8 (8),  
151 and mapped against the GRCh38 genome using minimap 2.24 (9) to remove host reads.  
152 Where possible given input sequencing depth, retained reads were assembled with flye 2.9  
153 (10) and parameters "--nano-raw --meta -- iterations 3". Whole metagenome assemblies were  
154 polished with Oxford Nanopore Medaka 1.6.1 and parameters "-m r941\_min\_fast\_g303" (11,  
155 12). Binning of assembled metagenomes into metagenomic bins was performed with MaxBin  
156 2.2.7 (13) and MetaBAT 2.15 (12). Bins were unified using DASTool 1.1.5 (14). Resulting  
157 bins were post-processed to improve retainment of AMR marker genes from high quality  
158 unbinned contigs, as previously described (7). Taxonomy was assigned using Kraken2 (15)  
159 and visualised using Krona plots (<https://fordegenomics.github.io/direct>). Completeness and  
160 duplication of bins was assessed with BUSCO (16) and QUAST (17). For each sample, no  
161 more than one resulting bin had genome quality metrics compatible with downstream AST  
162 prediction. Downstream analysis was thus performed on whole metagenome assemblies to  
163 reduce loss of AMR information in the binning process. Metagenome assemblies were  
164 uploaded to the AREScloud web application, release 2022-10 (Ares Genetics GmbH, Vienna,  
165 AT) for genomic prediction of antimicrobial susceptibility. The platform used stacked

166 classification machine learning (ML) WGS-AST models trained on ARESdb (18), combined  
167 with rule-based resistance prediction via ResFinder 4 (19) to provide species-specific  
168 susceptibility/resistance (S/R) predictions. If no high-quality ML models were available in  
169 AREScloud for certain taxa, non-specific ResFinder 4 calls based only on generalized  
170 presence of antibiotic resistance genes were used, but were flagged as being lower confidence  
171 predictions. Where sequence data from cultured isolates and paired BC broth samples were  
172 available, *in silico* resistance gene profiles were determined by screening the draft assembled  
173 genomes against the NCBI resistance gene database using AMRFinderPlus (version 3.10.24)  
174 (20) with default parameters (90% sequence identity and 90% sequence coverage) and  
175 compared for concordance in the presence / absence of AMR genes across the sample types.  
176  
177 AST predictions for a total of 25 antibiotic compounds were generated, where appropriate  
178 and relevant for that species. True negatives (TN) were defined as data points where both the  
179 reference method (phenotypic AST) and the test method (AREScloud) returned a negative  
180 (i.e. susceptible) result; true positives (TP) where both methods returned a positive (i.e.  
181 resistant) result; false positives (FP) where the reference method returned a negative and the  
182 tested method returned a positive result; false negatives (FN), where the reference method  
183 returned a positive and the tested method returned a negative result. Very major error (VME)  
184 and major error (ME) rates were defined following CLSI M52 guidelines (21) as the fraction  
185 of cases identified as resistant by the reference method which were identified as susceptible  
186 by the tested method ( $FN / (FN + TP)$ ), and the fraction of cases identified as susceptible by  
187 the reference method which were identified as resistant by the tested method ( $FP / (FP +$   
188  $TN)$ ), respectively. Categorical agreement (CA) between results of WGS-AST and  
189 conventional AST were calculated ( $CA = (TN + TP) / (TN + FP + FN + TP)$ ) for  
190 antimicrobial-organism combinations.



191

## 192 *Conventional species identification and AST*

193 All genomics based species identification and AST results were compared to conventional  
194 phenotypic methods validated for clinical use at Pathology Queensland. Species identification  
195 was performed using MALDI-TOF (Vitek MS, bioMérieux) on pure cultured isolates, with  
196 AST performed by Vitek 2 automated broth microdilution (N-246 AST cards; bioMérieux),  
197 using EUCAST clinical breakpoints applicable at the time (22). For certain species (e.g.  
198 *Streptococcus pyogenes*) AST was undertaken using disk diffusion according to EUCAST  
199 methods (23), or by Etest (bioMérieux) where appropriate (e.g. penicillin for *Streptococcus*  
200 *pneumoniae*). For some species where EUCAST breakpoints were not available (e.g.  
201 *Aeromonas* spp.), CLSI breakpoints were applied. Conventional phenotypic testing reported  
202 for clinical use by the diagnostic laboratory was considered the reference standard against  
203 which genomic results were compared.

204

## 205 **RESULTS**

### 206 **Blood Culture Microorganisms**

207 A total of 66 positive blood culture samples, from 201 enrolled patients, demonstrated  
208 bacterial growth, from which 52 were included for further MG-WGS analysis, with  
209 exclusions reflecting non-bacterial growth (e.g. *Candida* sp.), missing samples or likely  
210 contaminants (e.g. mixed coagulase-negative staphylococci) that were not worked up further  
211 by the clinical laboratory (Figure 2; Supplementary Table S1). Samples included 27 gram-  
212 positive and 23 gram-negative bacterial species, with 2 samples showing polymicrobial  
213 growth (Table 2).

214

## 215 **Taxonomy identification of metagenomic samples and *in silico* predictive AST**

216 Samples were run either on a single flow cell, or multiplexed with up to 12 samples per flow  
217 cell, with a median sequencing yield per flow cell of 2.5 Gbp for multiplexed samples, and  
218 1.5 Gbp for single samples. Taxonomic identification of metagenomic samples yielded  
219 excellent agreement to genus level compared to conventional methods (50/52, 96.2%); for  
220 monomicrobial samples agreement was 100% (50/50). In two samples, genus-level  
221 agreement was obtained, with sequencing provided a more refined identification; the pipeline  
222 identified species belonging to *Enterobacter cloacae* complex (*E. hormaechei* for sample  
223 9420-58 and *E. asburiae* for sample 9420-32) in two samples reported as *E. cloacae* by  
224 phenotypic methods. The correct species level identity resulting from MG-WGS of both  
225 samples was confirmed by sequencing of the cultured isolates. For one polymicrobial sample  
226 the secondary pathogen (*E. cloacae*) reported by phenotypic methods was not apparent in the  
227 Kraken2 report of input reads, where only one of the cultured pathogens (*E. coli*) was  
228 identified. For another polymicrobial sample, the presence of *Staphylococcus hominis* was  
229 identified by phenotypic methods alongside *Proteus mirabilis*, but only ~ 15% of bacterial  
230 reads in the sample could be matched to genus *Staphylococcus* and were insufficient for  
231 predictive MG-AST. For one sample (9421-30), no identification was achieved due to  
232 inadequate input data; with only 145 very short reads (mean read length 191), thus no further  
233 processing was possible. Sequencing from an uninoculated blood culture broth revealed a  
234 very low number of reads (n=28) mapping to bacterial genomes (e.g. *E. coli*), compared to a  
235 mean number of reads of 271411 mapping to bacterial taxa for positive culture broths  
236 included in the MG-AST analysis.

237

238 A total of 470 phenotypic AST results with matched metagenomic AST calls were analysed.

239 As conventional AST was not routinely performed in all samples (e.g. likely contaminants,

240 anaerobic organisms), predictive MG-AST was only compared where phenotypic results  
241 were available. In addition, 2 polymicrobial samples were excluded. For an additional 6  
242 samples, neither exploratory nor high quality MG-AST predictions, were available (4  
243 samples had insufficient reads for assembly and in 2 samples, antibiotics reported by  
244 phenotypic methods, were not available in the AREScloud database). As such, a total of 42  
245 samples had both MG-AST and phenotypic AST calls compared, and for 24 samples, high  
246 quality AREScloud predictions were available.

247

248 Overall CA was 89.3% for 262 AST results across 24 samples for which quality MG-AST  
249 predictions were available, including 7 common BSI organisms (*Staphylococcus aureus*,  
250 *Enterococcus faecalis*, *Escherichia coli*, *Klebsiella aerogenes*, *Klebsiella pneumoniae*,  
251 *Streptococcus pneumoniae* and *Pseudomonas aeruginosa*), but with 12.1% VMEs (mainly  
252 seen in *E. coli* with tobramycin and trimethoprim-sulfamethoxazole, driven by a single *E. coli*  
253 sample with poor assembly metrics) and 10.5% MEs (mainly seen in *P. aeruginosa* against  
254 cefepime, ciprofloxacin, gentamicin and meropenem, *K. aerogenes* against ceftazidime and  
255 ceftriaxone, *E. coli* against amikacin, cephalosporin, ampicillin and ceftiofur, and *K.*  
256 *pneumoniae* against cephalosporin and ciprofloxacin) (Tables 3 and 5; Supplementary Table S2).

257

258 For all 470 AST predictions across 42 samples, including both high-quality and exploratory-  
259 only results, CA was 87.7%, with 28.4% VME and 8.3% MEs (Table 4). VMEs were mainly  
260 seen with one isolate of *Aeromonas* sp. (100%; false susceptibility for amoxicillin-  
261 clavulanate, meropenem and trimethoprim), *Pseudomonas aeruginosa* (100%; false  
262 susceptibility for ticarcillin-clavulanate), *E. coli* (31.6%; false susceptibility for tobramycin,  
263 trimethoprim-sulfamethoxazole and ticarcillin-clavulanate), *Ochrobactrum anthropi* (33.3%;  
264 false susceptibility for ceftriaxone), *Staphylococcus haemolyticus* (50%; false susceptibility

265 for cephalothin, ciprofloxacin, rifampicin, tetracycline) and *Staphylococcus epidermidis*  
266 (20%; false susceptibility for cephalothin, ciprofloxacin and teicoplanin). MEs were seen in  
267 *Pseudomonas aeruginosa* (45.5%; false resistance for cefepime, ceftazidime, ciprofloxacin,  
268 meropenem) and *Klebsiella pneumoniae* (11.1%, false resistance for cephalothin, ceftazidime,  
269 and ciprofloxacin) (Supplementary Table S2). Not all of the tested compounds achieved  
270 satisfactory performance even when high quality predictions were achieved, with CA ranging  
271 from >95% (for amoxicillin-clavulanate, gentamicin, erythromycin, fusidic acid, ticarcillin-  
272 clavulanate and vancomycin) to as low as 55.6% for cephalothin, with high rates of VMEs for  
273 trimethoprim-sulfamethoxazole (66.7%), trimethoprim (25%) and tobramycin (100%) (Table  
274 6). The only agents that would pass acceptance criteria (>95% CA, <3% ME and <1.5%  
275 VME) even when only using high quality predictions, would be amoxicillin-clavulanate,  
276 erythromycin and fusidic acid. While vancomycin and ticarcillin-clavulanate had 100% CA  
277 and no MEs, the lack of resistant isolates precluded calculation of the rate of VMEs.

278

279 Detection of AMR genes from nanopore generated assemblies of bacterial genomes from BC  
280 broths showed some discrepancies compared to Illumina-based sequencing of pure cultured  
281 isolates (Figure 3), although several of these reflected more specific allele calls from  
282 sequencing pure isolates (e.g. *bla*<sub>CTX-M</sub> from MG-WGS, but *bla*<sub>CTX-M-15</sub> from pure isolate).  
283 Illumina-based WGS of pure isolates detected a median of 3 additional AMR gene targets  
284 (range -1 to 14; IQR 1-5). In only a single sample did nanopore detect one more AMR gene  
285 target than Illumina.

286

287 In terms of potential turn-around times for direct nanopore sequencing from blood cultures;  
288 pre-sequencing steps took ~4 hours, including: a) host DNA reduction, ~2 hours, b) DNA  
289 Extraction, ~30 minutes, c) DNA amplification, ~1 hour, and d) DNA Library prep, ~30

290 minutes. Adequate data for downstream processing would usually be achieved within ~4  
291 hours, but flow cells were run up to 12 hours for single samples, and 72 hours for multiplexed  
292 samples. The predictive MG-AST calls from AREScloud were available within ~ 1 hour. As  
293 such, the potential turn-around time from flagging of a positive blood culture to report  
294 generation, could be achieved within 9-17 hours, potentially faster than conventional AST  
295 methods and Illumina-based methods (up to 48 hours, or longer).

296

## 297 **DISCUSSION**

298 We describe a nanopore-based MG-WGS approach using positive blood culture broth for  
299 pathogen detection and taxonomic classification. In monomicrobial infections, the  
300 performance is encouraging, with 100% agreement to genus level. Polymicrobial samples  
301 remain challenging, with only one of two pathogens identified in samples encountered in this  
302 study. In two samples with species belonging to the *E. cloacae* complex, MG-WGS  
303 identification was more accurate than conventional methods, although discrimination by  
304 MALDI-TOF of these species is known to be problematic, without additional analysis (24,  
305 25). Sequencing directly from blood samples to detect pathogenic bacteria in patients with  
306 sepsis and bloodstream infection, is limited by low loads of bacterial DNA in blood at the  
307 time of presentation, high concentrations of human DNA and challenges in discriminating  
308 background low-level contaminating DNA (26, 27). Adding a culture-amplification step by  
309 sequencing from positive blood culture broths, as described in this study, increases the  
310 amount of bacteria DNA available for sequencing.

311

312 A key advance in the application of metagenomic diagnostics direct from clinical samples,  
313 would be the ability to accurately predict antimicrobial susceptibility, independently of  
314 conventional culture-based methods. However, the presence or absence of resistance genes

315 does not always predict the phenotype, which may be modified by gene expression, gene  
316 copy number and other post-translational effects (28). The machine-learning algorithm used  
317 in this study is based on a large sample bank with matched whole genome sequenced clinical  
318 isolates and AST results collected from several international centres (18). Such an approach  
319 has advantages in that the algorithm does not require a clear understanding of the association  
320 between genotype and phenotype, but will learn to use relevant genomic features if supplied  
321 with adequate amounts of data.

322

323 The use of direct metagenomic sequencing and WGS-AST from positive blood culture broths  
324 holds some promise, and nanopore long-read sequencing using MinION offers potential time  
325 advantages over Illumina-based approaches. Accuracy of pathogen identification was similar  
326 to results previously achieved with Illumina (95% species-level agreement) (5). However,  
327 using nanopore sequencing chemistries, flow cells and base-callers available at the time of  
328 study, MG-AST predictions based on nanopore data were considerably less accurate than  
329 Illumina-based methods, where CA of >95% was demonstrated for common gram-negative  
330 pathogens against 17 antimicrobials (with an overall 11% VME rate) (5). Nanopore  
331 sequencing in some samples resulted in significant fragmentation and incompleteness of  
332 assembled genomes, caused by an insufficient number of reads and low average read length  
333 in a subset of data, as well as lower depth of sequencing compared with Illumina. In addition,  
334 reads overall exhibited low per-base accuracy (average Phred score of 10.48, i.e.  
335 approximately 90% accuracy), likely due to base-calling with the "fast" profile and the use of  
336 an older versions of the Guppy base-caller (v5.0.16; and v3.2.9 used in earlier sequencing  
337 runs). Additional work is needed to assess the performance of current nanopore consumables  
338 (e.g. R10.4.1 flow cells and kit 14 chemistry), which are reported to achieve very high  
339 sequencing accuracies (29), and more current base-calling software. The high rates of

340 MEs/VMEs encountered in common species in this study, would currently preclude  
341 application for clinical use. CLSI M52 guidelines recommend that new AST systems  
342 demonstrate CA  $\geq 90\%$  and rates of MEs and VMEs  $< 3\%$  (21), although given the high risk  
343 of VMEs to patient care, the FDA stipulates VME rates to be  $< 1.5\%$  (30). However, it  
344 should be noted that some of these errors occurred in less critical or uncommonly prescribed  
345 species/antibiotic combinations (e.g. *E. coli* and tobramycin). It is hoped that errors could  
346 also be mitigated by database enhancement and training of the algorithms on a larger number  
347 and broader range of organisms. The application of sequencing from blood cultures may also  
348 allow faster identification of slow-growing or fastidious organisms. One potential approach to  
349 reduce time to reporting, might be the early sampling of blood culture broths, before they flag  
350 positive on automated detections systems. In this way, there may be adequate pathogen load  
351 to undertake sequencing, while reducing the overall turn-around time.

352

353 Limitations to this study are acknowledged. While samples included in the study were  
354 prospectively collected, and included most common species causing sepsis, a more extensive  
355 range of pathogens, including diverse AMR phenotypes would need to be assessed to  
356 understand the reliability, broader applicability and clinical utility of this approach.  
357 Furthermore, our collection included few samples with resistance to some agents, inflating  
358 VME rate in some species/antibiotic combinations. For example, there were only two  
359 *Pseudomonas aeruginosa* isolates with resistance to any antimicrobial tested; with resistance  
360 to ticarcillin-clavulanate that were both falsely reported as susceptible by MG-AST, leading  
361 to a 100% VME rate (albeit only from low-quality exploratory predictions). The absence of  
362 any resistances in the *Pseudomonas* samples to other agents precluded the ability to calculate  
363 any VMEs for other antibiotics using high-quality predictions. It is also acknowledged that  
364 Vitek 2 AST is not a reference method for MIC determination (such as broth microdilution or

365 agar dilution) and is an imperfect standard for comparison, despite being commonly used in  
366 clinical diagnostic laboratories. Additionally, improvements in nanopore flow cell technology  
367 have occurred since this study was performed, including the possibility of adaptive  
368 sequencing that can actively exclude human DNA during the sequencing process (31), which  
369 may also further improve the application of these methods.

370

### 371 **Conclusions**

372 Direct metagenomic sequencing from positive blood culture broths in patients with sepsis is  
373 feasible and can provide accurate species-level identification of causative pathogens,  
374 especially in monomicrobial infections. Predictive AST shows promise for some bacterial  
375 species and antibiotic combinations, but is sub-optimal for a number of common pathogens  
376 with unacceptably high VME rates driven by less reliable calls for certain species and drug  
377 combinations. Diagnostic performance characteristics were marginally improved by only  
378 accepting results where high-quality predictions were available. Nanopore-based approaches  
379 may be faster and provide data in real time, but improvements in accuracy across a broader  
380 range of organisms are required before it can be considered for clinical use. Improved  
381 performance should be achievable with training of ML algorithms on larger and more diverse  
382 datasets, and masking of results where poor performance of certain species and drug  
383 combinations are recognised. Furthermore, ongoing developments in the accuracy of rapid  
384 sequencing technologies, should lead to improved performance of these methods for eventual  
385 diagnostic use.

386

### 387 **Acknowledgements and funding**

388 This work was funded by a grant from the Queensland Genomics Health Alliance (QGHA;  
389 subsequently Queensland Genomics) clinical implementation, innovation and incubation



390 program and by a Brisbane Diamantina Health Partners Health System Improvement Ideas  
391 Grant (MRFF Rapid Applied Research Translation Program). Patrick Harris was supported  
392 by an Early Career Fellowship from the National Health and Medical Research Council  
393 (GNT1157530). Jason Roberts would like to acknowledge funding from the Australian  
394 National Health and Medical Research Council for a Centre of Research Excellence  
395 (APP2007007) and an Investigator Grant (APP2009736) as well as an Advancing  
396 Queensland Clinical Fellowship. Adam Irwin is supported by a National Health and Medical  
397 Research Council Investigator grant (GNT1197743). We would like to acknowledge the input  
398 and support of Thom Cuddihy, Cameron Buckley, Jason Meyer, Kara Brady, Cheryl Fourie,  
399 Natalie Sharp, Luminita Vlad, Scott A. Beatson, Julia Clark, Krispin Hajkowitz, Haakon  
400 Bergh and David Whiley.

401

#### 402 **Data availability**

403 Raw sequence reads have been uploaded to NCBI under Bioproject PRJNA982891.

404 Taxonomic classifications for blood culture samples can be visualised here:

405 <https://fordegenomics.github.io/direct>

406

#### 407 **Conflicts of interest**

408 Lukas Lüftinger and Stephan Beisken are employees of Ares Genetics. Patrick Harris reports  
409 research grants from Gilead, and has served on advisory boards for OpGen, Merck and  
410 Sandoz, has received honoraria from OpGen, Sandoz, Pfizer and BioMerieux. David Paterson  
411 reports grants from Shionogi, Pfizer, Merck and bioMerieux, and consultancies with the  
412 AMR Action Fund, Entasis, QPex, Spero, VenatoRx, Pfizer, Merck, Gilead, bioMerieux and  
413 Accelerate Diagnostics. Jason A. Roberts reported grants from Qpex, Gilead, Pfizer, Sandoz,  
414 MSD, Summit Pharma and Cipla. Adam Irwin has received research grants and honoraria

415 from Gilead, and honoraria from bioMerieux unrelated to this work. All other authors declare  
416 no conflicts of interest. Jason Roberts reported grants from Qpex, Gilead, Pfizer, Sandoz,  
417 MSD, Summit Pharma and Cipla.  
418

## References

- 419  
420  
421 1. Buehler SS, Madison B, Snyder SR, Derzon JH, Cornish NE, Saubolle MA, Weissfeld AS,  
422 Weinstein MP, Liebow EB, Wolk DM. 2016. Effectiveness of Practices To Increase  
423 Timeliness of Providing Targeted Therapy for Inpatients with Bloodstream Infections: a  
424 Laboratory Medicine Best Practices Systematic Review and Meta-analysis. *Clin Microbiol*  
425 *Rev* 29:59-103.
- 426 2. Sinha M, Jupe J, Mack H, Coleman TP, Lawrence SM, Fraley SI. 2018. Emerging  
427 Technologies for Molecular Diagnosis of Sepsis. *Clin Microbiol Rev* 31:e00089-17.
- 428 3. Hindiyeh M, Smollan G, Grossman Z, Ram D, Robinov J, Belausov N, Ben-David D, Tal I,  
429 Davidson Y, Shamiss A, Mendelson E, Keller N. 2011. Rapid detection of blaKPC  
430 carbapenemase genes by internally controlled real-time PCR assay using bactec blood culture  
431 bottles. *J Clin Microbiol* 49:2480-4.
- 432 4. Taxt AM, Avershina E, Frye SA, Naseer U, Ahmad R. 2020. Rapid identification of  
433 pathogens, antibiotic resistance genes and plasmids in blood cultures by nanopore sequencing.  
434 *Sci Rep* 10:7622.
- 435 5. Bauer MJ, Peri AM, Luftinger L, Beisken S, Bergh H, Forde BM, Buckley C, Cuddihy T, Tan  
436 P, Paterson DL, Whiley DM, Harris PNA. 2022. Optimized Method for Bacterial Nucleic  
437 Acid Extraction from Positive Blood Culture Broth for Whole-Genome Sequencing,  
438 Resistance Phenotype Prediction, and Downstream Molecular Applications. *J Clin Microbiol*  
439 60:e0101222.
- 440 6. Irwin AD, Coin LJM, Harris PNA, Cotta MO, Bauer MJ, Buckley C, Balch R, Kruger P,  
441 Meyer J, Shekar K, Brady K, Fourie C, Sharp N, Vlad L, Whiley D, Beatson SA, Forde BM,  
442 Paterson D, Clark J, Hajkowicz K, Raman S, Bialasiewicz S, Lipman J, Schlapbach LJ,  
443 Roberts JA. 2021. Optimising Treatment Outcomes for Children and Adults Through Rapid  
444 Genome Sequencing of Sepsis Pathogens. A Study Protocol for a Prospective, Multi-Centre  
445 Trial (DIRECT). *Front Cell Infect Microbiol* 11:667680.

- 446 7. Luftinger L, Majek P, Rattei T, Beisken S. 2023. Metagenomic Antimicrobial Susceptibility  
447 Testing from Simulated Native Patient Samples. *Antibiotics (Basel)* 12:366.
- 448 8. De Coster W, D'Hert S, Schultz DT, Cruts M, Van Broeckhoven C. 2018. NanoPack:  
449 visualizing and processing long-read sequencing data. *Bioinformatics* 34:2666-2669.
- 450 9. Li H. 2018. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* 34:3094-  
451 3100.
- 452 10. Kolmogorov M, Yuan J, Lin Y, Pevzner PA. 2019. Assembly of long, error-prone reads using  
453 repeat graphs. *Nat Biotechnol* 37:540-546.
- 454 11. Nurk S, Meleshko D, Korobeynikov A, Pevzner PA. 2017. metaSPAdes: a new versatile  
455 metagenomic assembler. *Genome Res* 27:824-834.
- 456 12. Li D, Luo R, Liu CM, Leung CM, Ting HF, Sadakane K, Yamashita H, Lam TW. 2016.  
457 MEGAHIT v1.0: A fast and scalable metagenome assembler driven by advanced  
458 methodologies and community practices. *Methods* 102:3-11.
- 459 13. Wu YW, Simmons BA, Singer SW. 2016. MaxBin 2.0: an automated binning algorithm to  
460 recover genomes from multiple metagenomic datasets. *Bioinformatics* 32:605-7.
- 461 14. Sieber CMK, Probst AJ, Sharrar A, Thomas BC, Hess M, Tringe SG, Banfield JF. 2018.  
462 Recovery of genomes from metagenomes via a dereplication, aggregation and scoring  
463 strategy. *Nat Microbiol* 3:836-843.
- 464 15. Wood DE, Lu J, Langmead B. 2019. Improved metagenomic analysis with Kraken 2.  
465 *Genome Biol* 20:257.
- 466 16. Manni M, Berkeley MR, Seppey M, Zdobnov EM. 2021. BUSCO: Assessing Genomic Data  
467 Quality and Beyond. *Curr Protoc* 1:e323.
- 468 17. Gurevich A, Saveliev V, Vyahhi N, Tesler G. 2013. QUASt: quality assessment tool for  
469 genome assemblies. *Bioinformatics* 29:1072-5.
- 470 18. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler  
471 A, Posch AE. 2020. Species Identification and Antibiotic Resistance Prediction by Analysis  
472 of Whole-Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the  
473 Unyvero Lower Respiratory Tract Infection Trial. *J Clin Microbiol* 58:e00273-20.

- 474 19. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,  
475 Rebelo AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK,  
476 Stingl K, Nguyen M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum  
477 MF, Duggett NA, Kempf I, Nykasenoja S, Olkkola S, Wiczorek K, Amaro A, Clemente L,  
478 Mossong J, Losch S, Ragimbeau C, Lund O, Aarestrup FM. 2020. ResFinder 4.0 for  
479 predictions of phenotypes from genotypes. *J Antimicrob Chemother* 75:3491-3500.
- 480 20. Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J, Haft DH, Hoffmann  
481 M, Pettengill JB, Prasad AB, Tillman GE, Tyson GH, Klimke W. 2021. AMRFinderPlus and  
482 the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial  
483 resistance, stress response, and virulence. *Sci Rep* 11:12728.
- 484 21. Clinical and Laboratory Standards Institute. 2015. Verification of Commercial Microbial  
485 Identification and Antimicrobial Susceptibility Testing Systems, 1st Edition, 1st ed. CLSI.
- 486 22. European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for  
487 interpretation of MICs and zone diameters version 9. EUCAST.
- 488 23. Matuschek E, Brown DF, Kahlmeter G. 2014. Development of the EUCAST disk diffusion  
489 antimicrobial susceptibility testing method and its implementation in routine microbiology  
490 laboratories. *Clin Microbiol Infect* 20:O255-66.
- 491 24. Wang W, Xi H, Huang M, Wang J, Fan M, Chen Y, Shao H, Li X. 2014. Performance of  
492 mass spectrometric identification of bacteria and yeasts routinely isolated in a clinical  
493 microbiology laboratory using MALDI-TOF MS. *J Thorac Dis* 6:524-33.
- 494 25. Godmer A, Benzerara Y, Normand AC, Veziris N, Gallah S, Eckert C, Morand P, Piarroux R,  
495 Aubry A. 2021. Revisiting Species Identification within the *Enterobacter cloacae* Complex by  
496 Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. *Microbiol  
497 Spectr* 9:e0066121.
- 498 26. Gu W, Deng X, Lee M, Sucu YD, Arevalo S, Stryke D, Federman S, Gopez A, Reyes K, Zorn  
499 K, Sample H, Yu G, Ishpuniani G, Briggs B, Chow ED, Berger A, Wilson MR, Wang C, Hsu  
500 E, Miller S, DeRisi JL, Chiu CY. 2021. Rapid pathogen detection by metagenomic next-  
501 generation sequencing of infected body fluids. *Nat Med* 27:115-124.

- 502 27. Trung NT, Hien TT, Huyen TT, Quyen DT, Van Son T, Hoan PQ, Phuong NT, Lien TT, Binh  
503 MT, Van Tong H, Meyer CG, Velavan TP, Song le H. 2016. Enrichment of bacterial DNA  
504 for the diagnosis of blood stream infections. *BMC Infect Dis* 16:235.
- 505 28. Forde BM, De Oliveira DMP, Falconer C, Graves B, Harris PNA. 2022. Strengths and  
506 caveats of identifying resistance genes from whole genome sequencing data. *Expert Review*  
507 *of Anti-infective Therapy* 20:533-547.
- 508 29. Sereika M, Kirkegaard RH, Karst SM, Michaelsen TY, Sorensen EA, Wollenberg RD,  
509 Albertsen M. 2022. Oxford Nanopore R10.4 long-read sequencing enables the generation of  
510 near-finished bacterial genomes from pure cultures and metagenomes without short-read or  
511 reference polishing. *Nat Methods* 19:823-826.
- 512 30. Humphries RM, Ambler J, Mitchell SL, Castanheira M, Dingle T, Hindler JA, Koeth L, Sei  
513 K, Development CM, Standardization Working Group of the Subcommittee on Antimicrobial  
514 Susceptibility T. 2018. CLSI Methods Development and Standardization Working Group  
515 Best Practices for Evaluation of Antimicrobial Susceptibility Tests. *J Clin Microbiol*  
516 56:e01934-17.
- 517 31. Martin S, Heavens D, Lan Y, Horsfield S, Clark MD, Leggett RM. 2022. Nanopore adaptive  
518 sampling: a tool for enrichment of low abundance species in metagenomic samples. *Genome*  
519 *Biol* 23:11.
- 520
- 521

522 **TABLES**

523 **Table 1:** Inclusion and exclusion criteria

<i>Inclusion criteria</i>	<i>Exclusion criteria</i>
a) Age >1 month	a) inability to gain informed consent
b) admitted to ICU	b) neonates (<1 month age)
c) decision to treat for suspected sepsis <sup>†</sup>	c) imminent death likely
d) blood cultures collected within 12h	d) palliative care intent
e) commenced on IV antibiotics within 24h, or a change in antibiotics initiated within 24h for a new episode of infection	e) on renal replacement therapy *
	f) use of extra-corporeal membrane oxygenation (ECMO) *

\* necessary as the main study included therapeutic drug monitoring and dose optimisation

<sup>†</sup> defined as suspected / proven infection with evidence of end organ dysfunction

524

525

526 **Table 2: Species identification by conventional methods**

Species	N
<b>Gram-positive (N=27)</b>	
<i>Staphylococcus aureus</i>	10
<i>Staphylococcus epidermidis</i>	7
<i>Streptococcus pneumoniae</i>	2
<i>Streptococcus pyogenes</i>	1
Group C <i>Streptococcus</i>	1
<i>Staphylococcus capitis</i>	1
<i>Staphylococcus lugdunensis</i>	1
<i>Staphylococcus haemolyticus</i>	1
<i>Enterococcus faecalis</i>	1
<i>Clostridium perfringens</i>	1
<i>Eggerthella lenta</i>	1
<b>Gram-negative (N=23)</b>	
<i>Escherichia coli</i>	7
<i>Enterobacter cloacae</i> complex	4
<i>Klebsiella (Enterobacter) aerogenes</i>	1
<i>Pseudomonas aeruginosa</i>	3
<i>Klebsiella pneumoniae</i>	3
<i>Haemophilus influenzae</i>	1
<i>Stenotrophomonas maltophilia</i>	1
<i>Aeromonas</i> sp.	1
<i>Prevotella intermedia</i>	1
<i>Ochrobactrum anthropi</i>	1
<b>Polymicrobial (N=2)</b>	
<i>Escherichia coli</i> + <i>Enterobacter cloacae</i>	1
<i>Proteus mirabilis</i> + <i>Staphylococcus hominis</i>	1
<b>Total</b>	<b>52</b>

527

528 **Table 3:** Performance of predictive MG-AST by species compared to Vitek 2, for samples  
 529 with high quality predictions

530

Species	N	Categorical Agreement (%)	Major Error (%)	Very Major Error (%)
<i>Staphylococcus aureus</i>	9	97.2	3.2	-
<i>Escherichia coli</i>	6	87.8	9.2	23.5
<i>Klebsiella pneumoniae</i>	3	93.8	6.5	0
<i>Pseudomonas aeruginosa</i>	3	52.4	47.6	-
<i>Enterococcus faecalis</i>	1	100	0	-
<i>Klebsiella aerogenes</i>	1	83.3	20	0
<i>Streptococcus pneumoniae</i>	1	66.7	33.3	-
<b>Overall</b>	<b>24</b>	<b>89.3</b>	<b>10.5</b>	<b>12.1</b>

531

Note: blank cells reflect no data for calculations (e.g. no resistance seen in that species by reference method)

532

533

534 **Table 4:** Performance of predictive MG-AST by species compared to Vitek 2, for all samples  
 535 including those with both high confidence and exploratory-only predictions



536

<b>Species</b>	<b>N</b>	<b>Categorical Agreement (%)</b>	<b>Major Error (%)</b>	<b>Very Major Error (%)</b>
<i>Staphylococcus aureus</i>	9	96.6	2.9	7.7
<i>Staphylococcus epidermidis</i>	7	85.5	7.1	35
<i>Escherichia coli</i>	6	86.5	8.7	30
<i>Enterobacter cloacae</i>	3	92.3	7.4	8.3
<i>Klebsiella pneumoniae</i>	3	90	11.1	0
<i>Pseudomonas aeruginosa</i>	3	50	45.5	100
<i>Aeromonas</i> sp.	1	70	0	100
<i>Enterococcus faecalis</i>	1	100	0	0
<i>Haemophilus influenzae</i>	1	100	0	-
<i>Klebsiella aerogenes</i>	1	93.3	9.1	0
<i>Ochrobactrum anthropi</i>	1	87.5	0	33.3
<i>Staphylococcus capitis</i>	1	83.3	0	50
<i>Staphylococcus haemolyticus</i>	1	67.7	0	57.1
<i>Staphylococcus lugdunensis</i>	1	100	0	0
<i>Streptococcus pneumoniae</i>	1	75	25	-
<i>Streptococcus pyogenes</i>	1	100	0	0
<i>Streptococcus dysgalactiae</i>	1	100	0	-
<b>Overall</b>	<b>42</b>	<b>87.7</b>	<b>8.3</b>	<b>28.4</b>

537

538

539

Note: blank cells reflect no data for calculations (e.g. no resistance seen in that species by reference method)

540

541 **Table 5:** Performance of MG-AST compared to Vitek MS, by species and compound, where  
 542 high quality predictions were available

<b>Species</b>	<b>Compound</b>	<b>CA (%)</b>	<b>ME (%)</b>	<b>VME (%)</b>
<i>Enterococcus faecalis</i>	Gentamicin	100	0	-
	Erythromycin	100	-	0
	Linezolid	100	0	-
	Teicoplanin	100	0	-
	Vancomycin	100	0	-
<i>Escherichia coli</i>	Amikacin	83.3	16.7	-
	Amoxicillin + clavulanic acid	100	0	-
	Ampicillin	83.3	33.3	0
	Cefazolin	40	75	0
	Cefepime	100	0	0
	Cefoxitin	83.3	16.7	-
	Ceftazidime	100	0	0
	Ceftriaxone	100	0	0
	Ciprofloxacin	100	0	0
	Gentamicin	100	0	0
	Meropenem	100	0	-
	Sulfamethoxazole + trimethoprim	60	0	66.7
	Tobramycin	83.3	0	100
	Trimethoprim	83.3	0	25
<i>Klebsiella (Enterobacter) aerogenes</i>	Amikacin	100	0	-
	Amoxicillin + clavulanic acid	100	-	0
	Cefazolin	100	-	0
	Ceftazidime	0	100	-
	Ceftriaxone	0	100	-
	Ciprofloxacin	100	0	-
	Gentamicin	100	0	-
	Meropenem	100	0	-
	Sulfamethoxazole + trimethoprim	100	0	-
	Ticarcillin + clavulanic acid	100	0	-
	Tobramycin	100	0	-
Trimethoprim	100	0	-	
<i>Klebsiella pneumoniae</i>	Amikacin	100	0	-
	Amoxicillin + clavulanic acid	100	0	0
	Cefazolin	66.7	33.3	-
	Ceftazidime	100	0	-
	Ceftriaxone	100	0	-
	Ciprofloxacin	50	50	-
	Gentamicin	100	0	-
	Meropenem	100	0	-

	Sulfamethoxazole + trimethoprim	100	0	-
	Ticarcillin + clavulanic acid	100	0	-
	Tobramycin	100	0	-
	Trimethoprim	100	0	-
<i>Pseudomonas aeruginosa</i>	Amikacin	100	0	-
	Cefepime	33.3	66.7	-
	Ceftazidime	0	100	-
	Ciprofloxacin	33.3	66.7	-
	Gentamicin	66.7	33.3	-
	Meropenem	33.3	66.7	-
	Tobramycin	100	0	-
<i>Staphylococcus aureus</i>	Benzylpenicillin	100	0	0
	Ciprofloxacin	100	0	-
	Clindamycin	88.9	14.3	0
	Erythromycin	100	0	0
	Fusidic acid	100	0	-
	Gentamicin	100	0	-
	Linezolid	100	0	-
	Mupirocin	88.9	11.1	-
	Rifampicin	88.9	11.1	-
	Teicoplanin	100	0	-
	Tetracycline	100	0	-
	Vancomycin	100	0	-
<i>Streptococcus pneumoniae</i>	Benzylpenicillin	0	100	-
	Erythromycin	100	0	-
	Vancomycin	100	0	-
<b>Overall</b>	<b>All agents</b>	<b>89.3</b>	<b>10.5</b>	<b>12.1</b>

543 Note: blank cells reflect no data for calculations (e.g. no susceptibility / resistance seen in that species by  
 544 reference method)  
 545

546

547 **Table 6:** Performance of MG-AST compared to Vitek MS for all compounds, where high  
548 quality predictions were available

<b>Compound</b>	<b>CA (%)</b>	<b>ME (%)</b>	<b>VME (%)</b>
Amikacin	92.3	7.7	-
Amoxicillin + clavulanic acid	100	0	0
Ampicillin	83.3	33.3	0
Benzylpenicillin	90	50	0
Cefazolin	55.6	57.1	0
Cefepime	77.8	25	0
Cefoxitin	83.3	16.7	-
Ceftazidime	69.2	33.3	0
Ceftriaxone	88.9	12.5	0
Ciprofloxacin	85.7	15	0
Clindamycin	88.9	14.3	0
Erythromycin	100	0	0
Fusidic acid	100	0	-
Gentamicin	95.5	4.8	0
Linezolid	100	0	-
Meropenem	83.3	16.7	-
Sulfamethoxazole + trimethoprim	77.8	0	66.7
Ticarcillin + clavulanic acid	100	0	-
Tobramycin	92.3	0	100
Trimethoprim	90	0	25
Vancomycin	100	0	-
<b>Overall</b>	<b>89.3</b>	<b>10.5</b>	<b>12.1</b>

549 Note: blank cells reflect no data for calculations (e.g. no resistance seen in that species by reference  
550 method)  
551

552

553 **FIGURE LEGENDS**

554 **Figure 1:** Workflow for metagenomic and conventional analysis of positive blood cultures

555

556 **Figure 2:** Flow diagram for sample inclusion.

557 BC = blood culture; WGS-AST = whole genome sequencing antimicrobial susceptibility testing; QC =

558 quality control



559

560 **Figure 3:** Heat map comparing antimicrobial resistance genes detected from Nanopore-


561 generated sequences from blood culture broth extractions, compared to Illumina-generated

562 sequences from pure cultured isolates from the same sample

# Adults and children with sepsis in ICU




Gram-negative




Gram-positive

## Metagenomics workflow



## Conventional workflow



**Enrolled with  
suspected sepsis  
n=201**

**Positive BC  
n=66**

**Metagenomic  
bacterial identification  
n=52**

**Predictive WGS-AST  
n=42**

**High-quality WGS-  
AST predictions  
n=24**

**Excluded n=135**  
No positive blood culture

**Excluded n=14**  
9 unavailable, 1 *Candida* sp.; 4 likely  
contaminants

**Excluded n=10**  
2 polymicrobial, 3 no AST performed  
(anaerobes), 4 failed QC metrics, 1 AST  
agents not included in Ares database

